Japanese Journal of Clinical Oncology · 2021 · 20 citations · 21 references
Our study indicates that peripheral absolute lymphocyte count, before nivolumab initiation, is a predictor of poor response in metastatic renal cell carcinoma. Additionally, increased absolute lymphocyte count, 1 month post-nivolumab initiation, can be a predictor of the effects of nivolumab.
21
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.5K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao, Claire A. Margolis, Wenhua Gao et al. · Science · 2018 · 1.3K citations · Full text
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri, Mayer Fishman, Bernard Escudier et al. · Clinical Cancer Research · 2016 · 290 citations · Full text